Clinical Trials
25 trialsNCT04858269 2026-05-22
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06295809 2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT07552558 2026-04-27
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT06561685 2026-04-20
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05047094 2026-04-06
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT06236425 2026-04-01
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT05027633 2026-03-20
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT06041802 2026-02-17
MK-3475A-E39
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05366166 2026-01-28
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06736379 2026-01-20
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
Phase 1 Recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT05859074 2025-12-03
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06912087 2025-12-02
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Phase 1 Recruiting
NCT04370587 2025-10-08
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Recruiting
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT04180215 2025-09-15
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
Phase 1/2 Completed
NCT04429542 2025-08-15
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
Phase 1 Recruiting
NCT02013154 2025-08-03
P102
Leap Therapeutics, Inc.
Phase 1 Completed
NCT04305795 2025-06-19
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
Phase 1/2 Active not recruiting